Navigation Links
Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
Date:10/20/2010

LONDON, Oct. 20 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the "Zamore Design Rules."  European patent number 1 633 890 titled "Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi" was published today in the European Patent Bulletin.  The European patent covers various breakthrough structural modification methods and compositions which Silence believes are fundamental for the development and commercialization of RNAi therapeutics with enhanced efficacy.

"The granting of this comprehensive patent in Europe is a significant milestone for Silence in our ongoing effort to build one of the world's leading RNAi intellectual property positions.  We have consistently built a strong IP estate around the Zamore technology in the U.S. and have now extended our global coverage to Europe with the granting of this critical patent," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We have often stated our belief that the 'Zamore Design Rules' represent significant IP to enable the process of bringing effective RNAi therapeutics to market.  With this latest patent grant from the EPO, we are excited to be able to offer potential collaborators or licensing partners access to this strongly protected Zamore technology in both the U.S. and Europe."

The issued patent's method and composition claims include:

  • Methods of enhancing the ability of an antisense strand of an RNAi agent to act as a guide strand
  • RNAi or siRNA agents for enhancing silencing of a target mRNA in a subject
  • Compositions for siRNA duplexes include pre-miRNA and shRNA and vectors to perform the methods described herein

Silence owns excl
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
2. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
3. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
4. Silence Therapeutics Appoints New Vice President of Research
5. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
6. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
7. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
8. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
9. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
10. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
11. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... TORONTO, Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: ... key terms with Toray,Industries Inc. of Japan to ... U.S. for Toraymyxin(TM), a therapeutic for the treatment ... the terms of the,agreement, the Company will seek ...
... InspireMD, Ltd.,announced today the enrollment of the first ... in acute myocardial infarction. The GUARD Study,(MGuard(TM) in ... safety and efficacy of MGuard(TM) in patients suffering ... were implanted,successfully with the MGuard(TM) Coronary Stent, in ...
... on Nano-Bio-Info-Cogno (NBIC) technologies and their interactions will ... Museum in Mountain View, California. The event ... participants to customize the event in a highly ... forecaster with over two decades experience exploring long-term ...
Cached Biology Technology:Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 2InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 3Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote 2Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote 3
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... announced today its involvement in an expanded access ... treatment for phenylketonuria (PKU), a rare genetic metabolic ... children, can result in severe mental retardation. Currently, ... access program at Nationwide Childrens. Under an ...
... Society and other institutions declare that improvements in ... double the number of tigers currently existing in the ... in the most recent edition of the journal Biological ... the Indian subcontinentcomprising India, Bangladesh, Bhutan, and Nepal. It ...
... Boulder, CO, USA - Topics include: continental deformation ... Mars; correlation of 200-million-year-old rocks between Britain and ... mass extinctions; rock weathering in Canada,s Mackenzie River ... how stable continents split in the absence of ...
Cached Biology News:Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2WCS study finds potential to double tiger numbers in South Asia 2November GEOLOGY and GSA TODAY Media Highlights 2November GEOLOGY and GSA TODAY Media Highlights 3November GEOLOGY and GSA TODAY Media Highlights 4November GEOLOGY and GSA TODAY Media Highlights 5November GEOLOGY and GSA TODAY Media Highlights 6November GEOLOGY and GSA TODAY Media Highlights 7November GEOLOGY and GSA TODAY Media Highlights 8November GEOLOGY and GSA TODAY Media Highlights 9November GEOLOGY and GSA TODAY Media Highlights 10
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Second Mitochondria Derived Activator of Caspase/DIABLO ... HEPES, pH 7.5 AVOID FREEZE/THAW CYCLES. Amino acid ... a carboxy terminal His•Tag ® sequence was ... . Smac/DIABLO is released along with cytochrome ...
... polyclonal to Decorin ( Abpromise ... Antigen: Synthetic peptide: IGPEVPDDRDFEPS ... acids 6-19 of Human Decorin (fragment ... proteoglycan II). Entrez ...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
Biology Products: